Herein, we assessed in depth the ability of IFN-β treatment to induce the production of sIFNAR2 and its potential relationship with the heterogeneity of the clinical response in MS patients treated with IFN-β. The gene discussed is IFNB1; the disease is myeloid sarcoma.